Abstract 445P
Background
Colorectal cancer (CRC) patients treated with curative intended surgery undergo 5-FU continuous infusion based chemotherapy using totally implantable central venous port system (TICVPS) in case of high-risk of recurrence. Approximately 30% patients relapse after the completion of therapy, especially within 2 years. Hence, many of high-risk CRC patients keep the TICVPS during 6-24 months after treatment, with regular intervals of TICVPS flushing. The manufacturer recommends monthly flushing for maintain TICVPS, however the interval of flushing lacks scientific evidence. The aim of this study is to investigate whether the extended maintenance intervals is safe and feasible.
Methods
A retrospective cohort was conducted in CRC patients who underwent curative intended surgery and perioperative chemotherapy using TICVPS between 2010 and 2017. Patient were enrolled if TICVPS was maintained at least 6 months with 3-month interval flushing using heparin, while patient who were recurred within 1 month, removed TICVPS within 6 months without definitive causes, or violation of flushing interval were excluded. The primary end points were the functional TICVPS maintenance rate.
Results
A total of 214 CRC patients underwent curative intended treatments during the study period. Among them, 6 patients (early recurrence within 1 month) and 54 patients (violation of flushing interval) were excluded, finally 154 patients were analyzed. Mean flushing interval was 98.4 days. At the Dec 2018, 35 patients kept the TICVPS, 92 were planned removal, and 25 were reused the TICVPS, while two patients had to unexpectedly remove due to TICVPS site infection and pain. Thus, the functional TICVPS maintenance rate was 98.8%. 38 patients were relapsed and 30 were treated with intravenous chemotherapy. Among them, 25 patients (83.3%) were reused the existing TICVPS without re-insertion procedure.
Conclusions
Our study demonstrated that 3-month interval flushing is safe and feasible in CRC patients. Extended time interval up to 3 months might be considered because it is compatible with CRC surveillance visit schedules and convenient for patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO10 - Rectal Follicular Dendritic Cell Sarcoma
Presenter: Kripa Bajaj
Session: Poster display session
Resources:
Abstract
YO11 - Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
Presenter: Lianyuan Tao
Session: Poster display session
Resources:
Abstract
YO12 - Case report of Hepatic EBV-associated smooth muscle tumor in AIDS patient
Presenter: Gorawich Kerkarchachai
Session: Poster display session
Resources:
Abstract
YO13 - IgG4-related pseudo-tumor of the kidney and multiple organ involvement mimicked malignancy
Presenter: Wasamol Mahaparn
Session: Poster display session
Resources:
Abstract
YO14 - Urachal Adenocarcinoma: Case Report
Presenter: Michelle Joane Alcantara
Session: Poster display session
Resources:
Abstract
YO15 - Concurrent Atezolizumab-Radiotherapy in Locally Recurrent Urinary Bladder Carcinoma: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO16 - Clear cell RCC with synchronous metastasis at transplanted kidney and bone in patient post Cadaveric donor kidney transplantation
Presenter: Punyaporn Cheewasathianchai
Session: Poster display session
Resources:
Abstract
YO17 - Serous ovarian cancer treated with palbociclib and letrozole
Presenter: Dai Wee Lee
Session: Poster display session
Resources:
Abstract
YO18 - A patient with Peutz-Jegher syndrome who incidentally found sex cord stromal tumor: a case report
Presenter: Pongput Pimsa
Session: Poster display session
Resources:
Abstract
YO19 - A case of CLL/SLL with transdifferentiation to dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm:The missing link?
Presenter: Yanping Chen
Session: Poster display session
Resources:
Abstract